乌克兰的干细胞治疗

Post-PCI Selection of Antithrombotic Therapy

Post-PCI Selection of Antithrombotic Therapy Improvements in antithrombotic pharmacotherapy have led to important reductions in complications after percutaneous coronary intervention. By John P. Vavalle, 医学博士, and Robert A. Harrington, MD Since the introduction of percutaneous coronary intervention (PCI) 多于 3 decades ago, the rates of procedural success and associated 阅读更多…

乌克兰的干细胞治疗

制药企业名单

雅培实验室. 阿特维斯集团 Adamed Alembic 有限公司 Alkem Lab. 艾尔建 Amoun Anton Hubner 安斯泰来制药欧洲 阿斯利康 Bausch & 隆拜耳 北京协和制药厂 Belco Pharma bene-Arzneimittel Beres Pharmaceuticals Ltd Berlin-Chemie AG (美纳里尼集团) Besins Healthcare Biomed Bionorica AG Biotehnos Boehringer Ingelheim Boiron Bosnalijek Cesra Arzneimittel GmbH & 钴. 阅读更多…

干细胞疗法